Publications
VST Cells
G-Rex®10
Publication Date: January 18, 2021
A single T-cell product simultaneously specific for four viruses (adenovirus, cytomegalovirus, Epstein-Barr virus and BK virus) and for Aspergillus fumigatus kept working in the presence of high-dose glucocorticoids after CRISPR/Cas9 disruption of the glucocorticoid receptor. Starting from 4.5 x 10^7 peripheral blood mononuclear cells drawn from 35 ml of donor blood, cells were pulsed with viral and fungal peptides, electroporated on day 3 with Cas9 ribonucleoproteins carrying the e2b guide RNA, and harvested after a 10-day culture, yielding on average 1.94 ± 0.5 x 10^8 cells. On-target cleavage averaged 21.4 ± 2.2% and 25.7 ± 2.6% of cells were receptor-negative. Edited cells retained me…
Publications
VST Cells
G-Rex®100M-CS
Publication Date: January 8, 2021
Virus-specific T cells for COVID-19 can be isolated from convalescent blood donations and expanded under GMP-compliant conditions to numbers sufficient for multiple allogeneic doses. Buffy coats from 15 convalescent donors, collected 34 to 56 days after symptom resolution, contained CD4 and CD8 memory T cells reactive to spike, nucleocapsid and membrane peptides. Cells secreting IFN-γ after peptide stimulation were captured, fed with irradiated non-target cells and expanded in G-Rex® vessels. After 14 days cultures were 87.95% T cells, mostly central memory CD4 cells, with yields of 1 to 4.6 × 10^9 cells; a second feeder stimulation gave 0.3 to 2 × 10^11 cells at day 21. Two leukapheresis…
Publications
TIL Cells
G-Rex®6 Well Plate, G-Rex®6M Well Plate
Publication Date: January 1, 2021
Changing the initial culture conditions of tumor-infiltrating lymphocyte (TIL) expansion shortened production to about three weeks and gave a TIL product rich in functional CD8+ T cells. TILs were grown from fresh and frozen tumor fragments of patients with various solid tumors in G-Rex® vessels with high-dose IL-2 and TIL stimulators, and compared with the standard 24-well plate protocol that takes 4 to 7 weeks. Culture success, defined as reaching 100,000 cells per fragment within four weeks, was 95.8% and 81.8% in the two stimulator conditions versus 33.3% with IL-2 alone. Both conditions favored CD8+ T-cell expansion. A subsequent rapid expansion in G-Rex® 6-well plates reached a mean…
Publications
CAR T Cells
Publication Date: December 24, 2020
In an autochthonous Kras-p53 mouse model of lung adenocarcinoma engineered to express human ROR1, ROR1 CAR-T cells given after cyclophosphamide lymphodepletion reduced tumor growth for only six weeks, all tumors eventually progressed, and more than half of tumor nodules were devoid of T cells. Adding oxaliplatin to the lymphodepletion regimen altered expression of 418 genes in lung tumors and activated iNOS+ macrophages that supplied Cxcl9, Cxcl10, Ccl5 and Cxcl16, significantly increasing CAR-T cell accumulation in tumors but not spleens by day 10. Early infiltration depended partly on CXCR6 and CCR5 and later infiltration on CXCR3. Oxaliplatin plus cyclophosphamide alone did not improve…
Publications
CAR T Cells, TCR T Cells
G-Rex®24 Well Plate
Publication Date: December 4, 2020
Testing of the MAGE-A12 cross-reactivity hypothesis for the neurotoxicity that halted a clinical MAGE-A3 TCR-T found no rare MAGE-A12 high-expressing cells in the brain, and pointed instead to a homologous EPS8L2 peptide. RNA FISH across about 3.2 million brain cells from 8 postmortem donors detected only a single cell with multiple dots. Public RNA-Seq showed MAGE-A12 at most 0.3 TPM in basal ganglia, while EPS8L2 reached 64 TPM in cerebellum. The A118T TCR killed HLA-A*02-expressing CAPAN-2 cells, which express EPS8L2 but not MAGE-A3 or -A12. Two newly isolated MAGE-A3 pMHC-directed CARs discriminated better against EPS8L2, the MAGE-A3112-120 CAR showing no detectable primary T-cell act…
Publications
CAR T Cells
Publication Date: November 22, 2020
Cynomolgus macaque T cells engineered with a piggyBac transposon to carry a CAR directed at the GM-CSF receptor (hGMR) caused no overt organ toxicity when returned to the same animals. Six macaques were used: three received autologous hGMR-CAR T cells at 3 × 10^5 CAR+ cells per kg and three received control T cells. Although the CAR T cells killed cynomolgus monocytes and M1 macrophages in vitro, monocyte counts, blood counts, coagulation values and tissue pathology showed no CAR-related damage over 14 days. The transgene fell to undetectable levels within a week, and IL-6 rose only transiently and mildly in one animal without symptoms of cytokine release syndrome.
Publications
VST Cells
G-Rex®10M
Publication Date: November 20, 2020
Virus-specific T cells directed against BK polyomavirus produced antiviral responses with minimal toxicity in transplant recipients in a phase 2 trial. Between June 2017 and December 2019, 38 stem cell transplant recipients and 3 solid organ transplant recipients were treated with donor-derived or third-party T cells, manufactured from donor blood in 11 to 12 days. Overall response was 86% for BK viremia, 100% for hemorrhagic cystitis and 87% for both conditions. Response per infusion for viremia was 95% with third-party and 75% with donor-derived products. No infusion reactions, de novo graft-versus-host disease or graft rejection were attributed to the infusions. Among responders with a…
Publications
T-Cells
G-Rex®24 Well Plate
Publication Date: November 19, 2020
A small soluble bispecific protein that binds both CD3 and CD28, called T-CEP, expanded human T cells ex vivo at femtomolar concentrations and skewed the product toward CD8+ cells with a less differentiated CD27+ phenotype. Used at 10 ng/mL (170 fM) with IL-2 over 12 days, it was about 150-fold lower in mass concentration than a commercial tetrameric antibody complex activator. Across five healthy donors, CD8+ T cells expanded a mean of 317-fold, and CD8+CD27+ cells expanded 325-fold, the highest in every donor. CD8+CD27+ cells made up a mean of 62.3% of viable lymphocytes on day 12, versus 34.3% to 38.1% with the other methods tested.
Publications
Other
Publication Date: November 16, 2020
A nanoparticle-based artificial antigen-presenting cell system, combined with a semi-automated enrichment and expansion process, produces multi-antigen-specific CD8+ T-cell products from the endogenous repertoire without genetic engineering. Superparamagnetic iron-oxide AIM nanoparticles carry HLA-A2 dimers and anti-CD28 antibody, are loaded with tumor peptides, and magnetically enrich antigen-specific cells from a leukopak after CD4+ depletion. Cells are then expanded for 14 days. In AML examples using five peptides, products averaged more than 20% antigen-specific cells, about 60% of cells showed 3–4 effector functions, and roughly 90% were Tscm, Tcm or Tem cells. Two phase 1/2 trials i…
Publications
CAR T Cells
Publication Date: November 9, 2020
Interleukin-8 receptor-linked CD70 CAR T cells (8R-70CAR) showed a favorable safety and manufacturing profile in preclinical work supporting a planned phase I glioblastoma trial. In C57BL/6J mice irradiated with 5 Gy and given 2 × 10^6 mouse 8R-70CAR T cells intravenously, no CAR T cell-related toxicity was observed, based on body weight, clinical signs, hematology, serum chemistry, cytokines and pathology of 12 vital organs. Human 8R-70CAR T cells made from glioblastoma patients' T cells were reactive against CD70-positive glioblastoma, measured by interferon-gamma production. They also expanded more than other CAR T cells tested, about 1200-fold over two weeks of production in the G-Rex…
Publications
CAR T Cells, TCR T Cells
G-Rex®24 Well Plate
Publication Date: November 9, 2020
The Quantitative Imaging-based Killing (QuIK) assay tracks primary human CAR-T and TCR-T cells cocultured with peptide-loaded A375 target cells in an IncuCyte imager. It separates antigen-dependent T cell proliferation from specific killing over time, using three dyes and per-cell rate calculations. Three HPV-directed receptors were compared at E:T ratios of 3:1, 1:1 and 1:3. Proliferation peaked at 72 hours and killing at 48 hours. The maximum kill rate occurred at about 24 hours for all constructs. Maximum killing fell at lower E:T ratios, while T cells proliferated more when cytotoxicity was lower. The HPV E7 CAR showed neither specific killing nor proliferation and had high tonic acti…
Publications
VST Cells
Publication Date: November 5, 2020
Virus-specific T cells generated from convalescent donors with mild COVID-19 selectively killed targets expressing SARS-CoV-2 antigens, supporting a banked, off-the-shelf product for high-risk patients. Donor cells were screened against peptide libraries covering 18 viral proteins, and eight immunodominant targets were chosen for manufacturing in a G-Rex® device with activating cytokines. Cells expanded a mean 29-fold (n=5) and were 97.1% CD3+, mostly CD4+ helper (85.5%) with 10.2% CD8+. All lines responded to the target antigens by IFNγ ELISpot, were Th1-polarized, and killed pepmix-loaded autologous PHA blasts without auto- or alloreactivity. The authors are advancing the product toward…
No manuscripts match your filters.